Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Respiratory Distress Syndrome
- Sponsor
- Xiangya Hospital of Central South University
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Analysis of serum proteins directly by proteomics analysis to identify new biomarkers of ARDS
- Last Updated
- 10 years ago
Overview
Brief Summary
The goal of this project is to find a series novel biomarkers by differential proteomic techniques that can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate.
Detailed Description
Acute respiratory distress syndrome(ARDS) has a very poor prognosis and high mortality. To improve the early diagnosis of ARDS, there is an urgent need for novel biomarkers of ARDS. The goal of this project is to find a series novel biomarkers by differential proteomic techniques that can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate. Clinical data and blood sample were recorded before treatment and after treatment. Acute Physiology And Chronic Health Evaluation III (APACHE III) scores were calculated at enrolment. Studying blood specimens from different period ARDS patients by proteomic analysis. It can provide information on a complex composition of proteins that are differentially expressed, which could be used for discovering high sensitivity and specificity ARDS biomarker.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The Berlin definition of acute respiratory distress syndrome
- •ATS definition of severe pneumonia
Exclusion Criteria
- •age below 18 years
- •pregnancy
- •Expected survival under 24 hours
Outcomes
Primary Outcomes
Analysis of serum proteins directly by proteomics analysis to identify new biomarkers of ARDS
Time Frame: 1 month
Secondary Outcomes
- PaO2/FiO2 ratio(baseline, day 3, day 5, 1week, 2 weeks)
- Mortality or multi-organ failure(1 month)
- APACHE III score(baseline, 1week, 2 weeks)